Our group has recently unraveled the critical role of inflammatory cancer-associated fibroblasts (iCAFs) and interleukin 1α (IL1α) signaling in therapy resistance, employing a murine rectal cancer model and patient-derived tumor organoids (PDO) [11]. This evidence concerns the gene IL1A and rectal cancer.